Literature DB >> 21903996

Mineralocorticoid receptor mutations and a severe recessive pseudohypoaldosteronism type 1.

Edwige-Ludiwyne Hubert1, Raphaël Teissier, Fábio L Fernandes-Rosa, Michel Fay, Marie-Edith Rafestin-Oblin, Xavier Jeunemaitre, Chantal Metz, Brigitte Escoubet, Maria-Christina Zennaro.   

Abstract

Pseudohypoaldosteronism type 1 (PHA1) is a rare genetic disease of mineralocorticoid resistance characterized by salt wasting and failure to thrive in infancy. Here we describe the first case of a newborn with severe recessive PHA1 caused by two heterozygous mutations in NR3C2, gene coding for the mineralocorticoid receptor (MR). Independent segregation of the mutations occurred in the family, with p.Ser166X being transmitted from the affected father and p.Trp806X from the asymptomatic mother Whereas the truncated MR(166X) protein was degraded, MR(806X) was expressed both at the mRNA and protein level. Functional studies demonstrated that despite its inability to bind aldosterone, MR(806X) had partial ligand-independent transcriptional activity. Partial nuclear localization of MR(806X) in the absence of hormone was identified as a prerequisite to initiate transcription. This exceptional case broadens the spectrum of clinical phenotypes of PHA1 and demonstrates that minimal residual activity of MR is compatible with life. It also suggests that rare hypomorphic NR3C2 alleles may be more common than expected from the prevalence of detected PHA1 cases. This might prove relevant for patient's care in neonatal salt losing disorders and may affect renal salt handling and blood pressure in the general population.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21903996      PMCID: PMC3279993          DOI: 10.1681/ASN.2011030245

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  22 in total

1.  [Sweat test].

Authors:  M Marchand; C Jarreau; M Chauffert; I Garcia; D Asselin; J P Thouvenot; A F Genest
Journal:  Ann Biol Clin (Paris)       Date:  1998 Mar-Apr       Impact factor: 0.459

2.  Localisation of pseudohypoaldosteronism genes to chromosome 16p12.2-13.11 and 12p13.1-pter by homozygosity mapping.

Authors:  S S Strautnieks; R J Thompson; A Hanukoglu; M J Dillon; I Hanukoglu; U Kuhnle; J Seckl; R M Gardiner; E Chung
Journal:  Hum Mol Genet       Date:  1996-02       Impact factor: 6.150

3.  A new human MR splice variant is a ligand-independent transactivator modulating corticosteroid action.

Authors:  M C Zennaro; A Souque; S Viengchareun; E Poisson; M Lombès
Journal:  Mol Endocrinol       Date:  2001-09

4.  Mineralocorticoid receptor mutations differentially affect individual gene expression profiles in pseudohypoaldosteronism type 1.

Authors:  Fábio L Fernandes-Rosa; Edwige-Ludiwyne Hubert; Jérome Fagart; Nicolas Tchitchek; Debora Gomes; Elodie Jouanno; Arndt Benecke; Marie-Edith Rafestin-Oblin; Xavier Jeunemaitre; Sonir R Antonini; Maria-Christina Zennaro
Journal:  J Clin Endocrinol Metab       Date:  2010-12-15       Impact factor: 5.958

5.  Antagonism in the human mineralocorticoid receptor.

Authors:  J Fagart; J M Wurtz; A Souque; C Hellal-Levy; D Moras; M E Rafestin-Oblin
Journal:  EMBO J       Date:  1998-06-15       Impact factor: 11.598

6.  A novel splice-site mutation in the gamma subunit of the epithelial sodium channel gene in three pseudohypoaldosteronism type 1 families.

Authors:  S S Strautnieks; R J Thompson; R M Gardiner; E Chung
Journal:  Nat Genet       Date:  1996-06       Impact factor: 38.330

Review 7.  Type I pseudohypoaldosteronism includes two clinically and genetically distinct entities with either renal or multiple target organ defects.

Authors:  A Hanukoglu
Journal:  J Clin Endocrinol Metab       Date:  1991-11       Impact factor: 5.958

Review 8.  Mineralocorticoid resistance.

Authors:  Maria-Christina Zennaro; Marc Lombès
Journal:  Trends Endocrinol Metab       Date:  2004-08       Impact factor: 12.015

9.  Colocalization of 11 beta-hydroxysteroid dehydrogenase type II and mineralocorticoid receptor in human epithelia.

Authors:  G Hirasawa; H Sasano; K Takahashi; K Fukushima; T Suzuki; N Hiwatashi; T Toyota; Z S Krozowski; H Nagura
Journal:  J Clin Endocrinol Metab       Date:  1997-11       Impact factor: 5.958

10.  Mutations in subunits of the epithelial sodium channel cause salt wasting with hyperkalaemic acidosis, pseudohypoaldosteronism type 1.

Authors:  S S Chang; S Grunder; A Hanukoglu; A Rösler; P M Mathew; I Hanukoglu; L Schild; Y Lu; R A Shimkets; C Nelson-Williams; B C Rossier; R P Lifton
Journal:  Nat Genet       Date:  1996-03       Impact factor: 38.330

View more
  5 in total

1.  A gain-of-function mutation in the CLCN2 chloride channel gene causes primary aldosteronism.

Authors:  Fabio L Fernandes-Rosa; Georgios Daniil; Ian J Orozco; Corinna Göppner; Rami El Zein; Vandana Jain; Sheerazed Boulkroun; Xavier Jeunemaitre; Laurence Amar; Hervé Lefebvre; Thomas Schwarzmayr; Tim M Strom; Thomas J Jentsch; Maria-Christina Zennaro
Journal:  Nat Genet       Date:  2018-02-05       Impact factor: 38.330

2.  A Novel SCNN1A Variation in a Patient with Autosomal-recessive Pseudohypoaldosteronism Type 1

Authors:  Mohammed Ayed Huneif; Ziyad Hamad Alhazmy; Anas M. Shoomi; Mohammed A. Alghofely; Humariya Heena; Aziza M. Mushiba; Abdulhamid AlSaheel
Journal:  J Clin Res Pediatr Endocrinol       Date:  2021-04-08

3.  Pseudohypoaldosteronism in a neonate presenting as life-threatening arrhythmia.

Authors:  Sudeep K Rajpoot; Carlos Maggi; Amrit Bhangoo
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2014-03-01

4.  CACNA1H Mutations Are Associated With Different Forms of Primary Aldosteronism.

Authors:  Georgios Daniil; Fabio L Fernandes-Rosa; Jean Chemin; Iulia Blesneac; Jacques Beltrand; Michel Polak; Xavier Jeunemaitre; Sheerazed Boulkroun; Laurence Amar; Tim M Strom; Philippe Lory; Maria-Christina Zennaro
Journal:  EBioMedicine       Date:  2016-10-04       Impact factor: 8.143

5.  Novel mutations in the SCNN1A gene causing Pseudohypoaldosteronism type 1.

Authors:  Jian Wang; Tingting Yu; Lei Yin; Jing Li; Li Yu; Ye Shen; Yongguo Yu; Yongnian Shen; Qihua Fu
Journal:  PLoS One       Date:  2013-06-06       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.